Fox Business - The Power to Prosper
Search Site

GlaxoSmithKline

Pandora shares get boost from ‘buy’ rating

FBN’s Adam Shapiro breaks down the day in the markets.

Read More

  1. Chinese police to brief media on GlaxoSmithKline

    FBN’s Liz MacDonald on the latest on the GlaxoSmithKline bribery probe.

  2. The next golden age of M&A

    Citigroup Institutional Clients Group vice Chairman Leon Kalvaria gives his outlook for the M&A market.

  3. AstraZeneca Plans Spin-Offs

    AstraZeneca announced faster-than-expected progress of its experimental cancer drugs and plans to spin off billions of dollars of non-core assets as it staked a clai...

  4. Zimmer to Buy Biomet In $13.35B Deal

    Medical device maker Zimmer Holdings Inc said it would buy orthopedic products company Biomet Inc in a deal valued at about $13.35 billion to broaden its portfolio o...

  5. What the GSK , Novartis Deal Means for Biotech

    The loud welcome given by investors to this week's deal for Novartis and GlaxoSmithKline to trade more than $20 billion of assets could trigger more pacts in the pha...

  6. Pharma Deal Frenzy: A Bid to Boost Profits

    High-priced pharmacy deals are all the rage this year as big drug companies stung by patent expirations attempt to offset losses and reduce risk and costs by joining...

  7. Amgen Slumps After 1Q Earnings Miss

    Amgen (NASDAQ:AMGN) said Tuesday its first-quarter profit dropped 25% amid lower-than-expected sales for the biopharmaceutical firm.The company reported net income o...

  8. Big news in pharma

    Altaira senior managing director Ralph Acampora on the Novartis M&A news and the landscape for pharmaceuticals.

  9. U.S. futures look for direction

    FBN’s Maria Bartiromo on U.S. futures and the $25 billion in Novartis deals.

  10. Novartis sees GSK's cancer drugs as potential blockbusters

    Novartis believes GlaxoSmithKline's cancer drugs Votrient, Tafinlar and Mekinist could have more than $1 billion in sales each, the head of the Swiss company's pharm...

  11. Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

    Over the past couple of days there has been news of several multi-billion dollar deals in the pharmaceutical sector.The big news came on Monday night when it began t...

  12. Novartis Announces Multi-Billion-Dollar Revamp

    Novartis (NYSE:NVS) is revamping its portfolio with a flurry of deals worth about $25 billion, as the Swiss pharmaceutical giant plans to swap assets with GlaxoSmith...

  1. More trouble ahead for GSK

    FBN’s Liz MacDonald on GlaxoSmithKline ’s new bribery allegations.

  2. Tiny implantable devices the future of medicine?

    GlaxoSmithKline Global R&D chairman Moncef Slaoui on the development of bioelectronic medicines.

  3. Market check: P, MRK, GSK

    FBN’s Lauren Simonetti with the latest on the markets.

  4. Market check: MRK, GSK , GM

    FBN’s Lauren Simonetti with the latest on the markets.

  5. Is it too late for investors to get on the Apple bandwagon?

    JohnsonBrunetti President Joel Johnson, Gary Goldberg Financial Services President Oliver Pursche and AverageJoeOptions.com founder Todd Horwitz on the outlook for stocks.

  6. UK regulators eye Glaxo

    FBN’s Jo Ling Kent on UK regulators bearing down on pharma giant GlaxoSmithKline .

  7. China charges ex-China GlaxoSmithKline head with bribery

    FBN’s Liz MacDonald on GlaxoSmithKline ’s alleged bribery charges.

‹ Prev12345Next ›
Freebase CC-BY
Source: GlaxoSmithKline on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL